Willner & Heller LLC Has $495,000 Position in Humana Inc. (NYSE:HUM)

Willner & Heller LLC grew its stake in Humana Inc. (NYSE:HUM) by 17.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,562 shares of the insurance provider’s stock after buying an additional 229 shares during the period. Willner & Heller LLC’s holdings in Humana were worth $495,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Quarry LP lifted its position in shares of Humana by 195.2% in the 4th quarter. Quarry LP now owns 124 shares of the insurance provider’s stock worth $57,000 after purchasing an additional 82 shares during the period. V Square Quantitative Management LLC boosted its position in Humana by 36.6% during the fourth quarter. V Square Quantitative Management LLC now owns 2,022 shares of the insurance provider’s stock valued at $926,000 after acquiring an additional 542 shares during the last quarter. EP Wealth Advisors LLC boosted its position in Humana by 1.6% during the fourth quarter. EP Wealth Advisors LLC now owns 2,294 shares of the insurance provider’s stock valued at $1,050,000 after acquiring an additional 37 shares during the last quarter. SageView Advisory Group LLC acquired a new stake in Humana during the 4th quarter worth about $652,000. Finally, B. Riley Wealth Advisors Inc. raised its position in shares of Humana by 15.8% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 2,041 shares of the insurance provider’s stock worth $936,000 after acquiring an additional 278 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

Humana stock traded up $6.63 during midday trading on Friday, reaching $258.07. The stock had a trading volume of 4,020,151 shares, compared to its average volume of 1,811,433. The firm has a market capitalization of $31.10 billion, a PE ratio of 16.07, a P/E/G ratio of 1.91 and a beta of 0.50. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $530.54. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm’s 50-day moving average price is $324.76 and its 200 day moving average price is $340.20.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. During the same period in the prior year, the company posted $8.94 EPS. Humana’s revenue was up 10.4% compared to the same quarter last year. As a group, research analysts predict that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.37%. Humana’s payout ratio is 22.04%.

Wall Street Analyst Weigh In

HUM has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their target price on Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 21st. Sanford C. Bernstein upgraded Humana from a “market perform” rating to an “outperform” rating and set a $308.00 target price for the company in a research note on Tuesday, October 8th. Barclays dropped their price target on Humana from $364.00 to $250.00 and set an “equal weight” rating on the stock in a research note on Thursday. TD Cowen downgraded Humana from a “buy” rating to a “hold” rating and decreased their price objective for the company from $402.00 to $261.00 in a report on Monday, October 7th. Finally, Jefferies Financial Group cut shares of Humana from a “buy” rating to a “hold” rating and cut their price target for the stock from $519.00 to $253.00 in a report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, nineteen have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $315.33.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.